CDK9-IN-45

• Description :

  CDK9-IN-45 (Compound B11) is a highly selective CDK9 inhibitor with IC50 values for CDK9 and CDK1 of 7.13 and 489.5 nM respectively. CDK9-IN-45 exhibits a potent inhibitory effect on colorectal cancer cells. CDK9-IN-45 induces cell apoptosis and leads to significant accumulation of ROS. CDK9-IN-45 activates Caspase-3, downregulates Mcl-1, XIAP, and c-Myc. CDK9-IN-45 can be used for research on colorectal cancer[1].

• Target :

  Apoptosis; Bcl-2 Family; Caspase; CDK; c-Myc; IAP; Reactive Oxygen Species (ROS)

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

• Field of Research :

  Cancer

• Smiles :

  FC1=CC=C(C2=CC=NC(NC3=CC(NN=C4C(N5CC6(COC6)C5)=O)=C4C=C3)=C2)C(OC)=C1

• Molecular Formula :

  C25H22FN5O3

• Molecular Weight :

  459.47

• References & Citations :

  [1]Sun X, et al. Design, synthesis, and activity evaluation of selective CDK9 inhibitors containing indazole fragments. Bioorg Chem. 2025 Oct 13;166:109083.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  Caspase 3; CDK1; CDK9; Mcl-1; XIAP